Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Influenza Virus | Review

Virus usurps alternative splicing to clear the decks for infection

Authors: Ruixue Li, Shenyan Gao, Huayuan Chen, Xiaozhan Zhang, Xia Yang, Jun Zhao, Zeng Wang

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Since invasion, there will be a tug-of-war between host and virus to scramble cellular resources, for either restraining or facilitating infection. Alternative splicing (AS) is a conserved and critical mechanism of processing pre-mRNA into mRNAs to increase protein diversity in eukaryotes. Notably, this kind of post-transcriptional regulatory mechanism has gained appreciation since it is widely involved in virus infection. Here, we highlight the important roles of AS in regulating viral protein expression and how virus in turn hijacks AS to antagonize host immune response. This review will widen the understandings of host-virus interactions, be meaningful to innovatively elucidate viral pathogenesis, and provide novel targets for developing antiviral drugs in the future.
Literature
1.
2.
Chow LT, Roberts JM, Lewis JB, Broker TR. A map of cytoplasmic RNA transcripts from lytic adenovirus type 2, determined by electron microscopy of RNA:DNA hybrids. Cell. 1977;11:819–36.PubMedCrossRef
3.
4.
Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40:1413–5.PubMedCrossRef
5.
6.
7.
Warf MB, Berglund JA. Role of RNA structure in regulating pre-mRNA splicing. Trends Biochem Sci. 2010;35:169–78.PubMedCrossRef
8.
9.
10.
Papasaikas P, Valcarcel J. The spliceosome: the ultimate RNA chaperone and sculptor. Trends Biochem Sci. 2016;41:33–45.PubMedCrossRef
11.
Graham SV, Faizo AAA. Control of human papillomavirus gene expression by alternative splicing. Virus Res. 2017;231:83–95.PubMedCrossRef
12.
Marasco LE, Kornblihtt AR. The physiology of alternative splicing. Nat Rev Mol Cell Biol. 2022;24:242–54.PubMedCrossRef
13.
Graveley BR. Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 2001;17:100–7.PubMedCrossRef
14.
15.
Gomez-Redondo I, Planells B, Navarrete P, Gutierrez-Adan A. Role of alternative splicing in sex determination in vertebrates. Sex Dev. 2021;15:381–91.PubMedCrossRef
16.
17.
Bonnal SC, Lopez-Oreja I, Valcarcel J. Roles and mechanisms of alternative splicing in cancer—implications for care. Nat Rev Clin Oncol. 2020;17:457–74.PubMedCrossRef
18.
Sehrawat S, Garcia-Blanco MA. RNA virus infections and their effect on host alternative splicing. Antiviral Res. 2023;210:105503.PubMedCrossRef
19.
Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol. 1993;67:6365–78.PubMedPubMedCentralCrossRef
20.
21.
22.
23.
24.
Himmelspach M, Cavaloc Y, Chebli K, Stévenin J, Gattoni R. Titration of serine/arginine (SR) splicing factors during adenoviral infection modulates E1A pre-mRNA alternative splicing. RNA. 1995;1:794–806.PubMedPubMedCentral
25.
Schmitt P, Gattoni R, Keohavong P, Stevenin J. Alternative splicing of E1A transcripts of adenovirus requires appropriate ionic conditions in vitro. Cell. 1987;50:31–9.PubMedCrossRef
26.
Gattoni R, Chebli K, Himmelspach M, Stevenin J. Modulation of alternative splicing of adenoviral E1A transcripts: factors involved in the early-to-late transition. Genes Dev. 1991;5:1847–58.PubMedCrossRef
27.
Dauksaite V, Akusjärvi G. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5’-splice site selection. Biochem J. 2004;381:343–50.PubMedPubMedCentralCrossRef
28.
Mayeda A, Krainer AR. Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell. 1992;68:365–75.PubMedCrossRef
29.
Caceres JF, Misteli T, Screaton GR, Spector DL, Krainer AR. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J Cell Biol. 1997;138:225–38.PubMedPubMedCentralCrossRef
30.
31.
Bourgeois CF, Popielarz M, Hildwein G, Stevenin J. Identification of a bidirectional splicing enhancer: differential involvement of SR proteins in 5’ or 3’ splice site activation. Mol Cell Biol. 1999;19:7347–56.PubMedPubMedCentralCrossRef
32.
Kreivi JP, Akusjärvi G. Regulation of adenovirus alternative RNA splicing at the level of commitment complex formation. Nucleic Acids Res. 1994;22:332–7.PubMedPubMedCentralCrossRef
33.
34.
35.
36.
Nevins JR, Wilson MC. Regulation of adenovirus-2 gene expression at the level of transcriptional termination and RNA processing. Nature. 1981;290:113–8.PubMedCrossRef
37.
Delsert C, Morin N, Klessig DF. cis-acting elements and a trans-acting factor affecting alternative splicing of adenovirus L1 transcripts. Mol Cell Biol. 1989;9:4364–71.PubMedPubMedCentral
38.
Dauksaite V, Akusjarvi G. Human splicing factor ASF/SF2 encodes for a repressor domain required for its inhibitory activity on pre-mRNA splicing. J Biol Chem. 2002;277:12579–86.PubMedCrossRef
39.
Huang TS, Nilsson CE, Punga T, Akusjarvi G. Functional inactivation of the SR family of splicing factors during a vaccinia virus infection. EMBO Rep. 2002;3:1088–93.PubMedPubMedCentralCrossRef
40.
Kanopka A, Muhlemann O, Petersen-Mahrt S, Estmer C, Ohrmalm C, Akusjarvi G. Regulation of adenovirus alternative RNA splicing by dephosphorylation of SR proteins. Nature. 1998;393:185–7.PubMedCrossRef
41.
Tormanen H, Backstrom E, Carlsson A, Akusjarvi G. L4–33K, an adenovirus-encoded alternative RNA splicing factor. J Biol Chem. 2006;281:36510–7.PubMedCrossRef
42.
Biasiotto R, Akusjarvi G. Regulation of human adenovirus alternative RNA splicing by the adenoviral L4-33K and L4-22K proteins. Int J Mol Sci. 2015;16:2893–912.PubMedPubMedCentralCrossRef
43.
Sommer S, Salditt-Georgieff M, Bachenheimer S, Darnell JE, Furuichi Y, Morgan M, Shatkin AJ. The methylation of adenovirus-specific nuclear and cytoplasmic RNA. Nucleic Acids Res. 1976;3:749–65.PubMedPubMedCentralCrossRef
44.
Price AM, Hayer KE, McIntyre ABR, Gokhale NS, Abebe JS, Della Fera AN, Mason CE, Horner SM, Wilson AC, Depledge DP, Weitzman MD. Direct RNA sequencing reveals m(6)A modifications on adenovirus RNA are necessary for efficient splicing. Nat Commun. 2020;11:6016.PubMedPubMedCentralCrossRef
45.
Price AM, Steinbock RT, Di C, Hayer KE, Li Y, Herrmann C, Parenti NA, Whelan JN, Weiss SR, Weitzman MD. Adenovirus prevents dsRNA formation by promoting efficient splicing of viral RNA. Nucleic Acids Res. 2022;50:1201–20.PubMedCrossRef
46.
Shin KH, Kim RH, Kang MK, Kim RH, Kim SG, Lim PK, Yochim JM, Baluda MA, Park NH. p53 promotes the fidelity of DNA end-joining activity by, in part, enhancing the expression of heterogeneous nuclear ribonucleoprotein G. DNA Repair (Amst). 2007;6:830–40.PubMedCrossRef
47.
Johansson C, Schwartz S. Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nat Rev Microbiol. 2013;11:239–51.PubMedCrossRef
48.
49.
Johansson C, Somberg M, Li X, Backstrom Winquist E, Fay J, Ryan F, Pim D, Banks L, Schwartz S. HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation. EMBO J. 2012;31:3212–27.PubMedPubMedCentralCrossRef
50.
Hao CY, Zheng YJ, Jonsson J, Cui XX, Yu HR, Wu CJ, Kajitani N, Schwartz S. hnRNP G/RBMX enhances HPV16 E2 mRNA splicing through a novel splicing enhancer and inhibits production of spliced E7 oncogene mRNAs. Nucleic Acids Res. 2022;50:3867–91.PubMedPubMedCentralCrossRef
51.
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550–60.PubMedCrossRef
52.
Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2018;26:158–68.PubMedCrossRef
53.
Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76–9.PubMedCrossRef
54.
Tang S, Tao M, McCoy JP Jr, Zheng ZM. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol. 2006;80:4249–63.PubMedPubMedCentralCrossRef
55.
Shally M, Alloul N, Jackman A, Muller M, Gissmann L, Sherman L. The E6 variant proteins E6I–E6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53. Virus Res. 1996;42:81–96.PubMedCrossRef
56.
Zheng ZM. Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression. J Biomed Sci. 2004;11:278–94.PubMedCrossRef
57.
Mesplede T, Gagnon D, Bergeron-Labrecque F, Azar I, Senechal H, Coutlee F, Archambault J. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol. 2012;86:94–107.PubMedPubMedCentralCrossRef
58.
Paget-Bailly P, Meznad K, Bruyère D, Perrard J, Herfs M, Jung AC, Mougin C, Prétet J-L, Baguet A. Comparative RNA sequencing reveals that HPV16 E6 abrogates the effect of E6*I on ROS metabolism. Sci Rep. 2019;9:5938.PubMedPubMedCentralCrossRef
59.
60.
Ajiro M, Tang S, Doorbar J, Zheng ZM. Serine/arginine-rich splicing factor 3 and heterogeneous nuclear ribonucleoprotein A1 regulate alternative RNA splicing and gene expression of human papillomavirus 18 through two functionally distinguishable cis elements. J Virol. 2016;90:9138–52.PubMedPubMedCentralCrossRef
61.
62.
McFarlane M, MacDonald AI, Stevenson A, Graham SV. Human papillomavirus 16 oncoprotein expression is controlled by the cellular splicing factor SRSF2 (SC35). J Virol. 2015;89:5276–87.PubMedPubMedCentralCrossRef
63.
Ho JSY, Zhu ZY, Marazzi I. Unconventional viral gene expression mechanisms as therapeutic targets. Nature. 2021;593:362–71.PubMedCrossRef
64.
65.
Cao S, Liu XL, Yu MR, Li J, Jia XJ, Bi YH, Sun L, Gao GF, Liu WJ. A nuclear export signal in the matrix protein of influenza A virus is required for efficient virus replication. J Virol. 2012;86:4883–91.PubMedPubMedCentralCrossRef
66.
Jackson D, Lamb RA. The influenza A virus spliced messenger RNA M mRNA3 is not required for viral replication in tissue culture. J Gen Virol. 2008;89:3097–101.PubMedCrossRef
67.
Wise HM, Hutchinson EC, Jagger BW, Stuart AD, Kang ZH, Robb N, Schwartzman LM, Kash JC, Fodor E, Firth AE, et al. Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain. PLoS Path. 2012;8:e1002998.CrossRef
68.
Shih SR, Krug RM. Novel exploitation of a nuclear function by influenza virus: the cellular SF2/ASF splicing factor controls the amount of the essential viral M2 ion channel protein in infected cells. EMBO J. 1996;15:5415–27.PubMedPubMedCentralCrossRef
69.
Shih SR, Nemeroff ME, Krug RM. The choice of alternative 5’ splice sites in influenza virus M1 mRNA is regulated by the viral polymerase complex. Proc Natl Acad Sci U S A. 1995;92:6324–8.PubMedPubMedCentralCrossRef
70.
Thompson MG, Munoz-Moreno R, Bhat P, Roytenberg R, Lindberg J, Gazzara MR, Mallory MJ, Zhang K, Garcia-Sastre A, Fontoura BMA, Lynch KW. Co-regulatory activity of hnRNP K and NS1-BP in influenza and human mRNA splicing. Nat Commun. 2018;9:2407.PubMedPubMedCentralCrossRef
71.
72.
Robb NC, Fodor E. The accumulation of influenza A virus segment 7 spliced mRNAs is regulated by the NS1 protein. J Gen Virol. 2012;93:113–8.PubMedCrossRef
73.
Muraki Y, Furukawa T, Kohno Y, Matsuzaki Y, Takashita E, Sugawara K, Hongo S. Influenza C virus NS1 protein upregulates the splicing of viral mRNAs. J Virol. 2010;84:1957–66.PubMedCrossRef
74.
Zheng M, Wang P, Song W, Lau SY, Liu S, Huang X, Mok BW, Liu YC, Chen Y, Yuen KY, Chen H. An A14U substitution in the 3’ noncoding region of the M segment of viral RNA supports replication of influenza virus with an NS1 deletion by modulating alternative splicing of M segment mRNAs. J Virol. 2015;89:10273–85.PubMedPubMedCentralCrossRef
75.
Calderon BM, Danzy S, Delima GK, Jacobs NT, Ganti K, Hockman MR, Conn GL, Lowen AC, Steel J. Dysregulation of M segment gene expression contributes to influenza A virus host restriction. PLoS Pathog. 2019;15:e1007892.PubMedPubMedCentralCrossRef
76.
77.
Dubois J, Terrier O, Rosa-Calatrava M. Influenza viruses and mRNA splicing: doing more with less. MBio. 2014;5:e0070-e00014.CrossRef
78.
79.
80.
Chung YT, Kuan CY, Liao GR, Albrecht RA, Tseng YY, Hsu YC, Ou SC, Hsu WL. A variant NS1 protein from H5N2 avian influenza virus suppresses PKR activation and promotes replication and virulence in mammals. Emerg Microbes Infect. 2022;11:2291–303.PubMedPubMedCentralCrossRef
81.
Garaigorta U, Ortin J. Mutation analysis of a recombinant NS replicon shows that influenza virus NS1 protein blocks the splicing and nucleo-cytoplasmic transport of its own viral mRNA. Nucleic Acids Res. 2007;35:4573–82.PubMedPubMedCentralCrossRef
82.
Fortes P, Beloso A, Ortin J. Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J. 1994;13:704–12.PubMedPubMedCentralCrossRef
83.
Alonso-Caplen FV, Nemeroff ME, Qiu Y, Krug RM. Nucleocytoplasmic transport: the influenza virus NS1 protein regulates the transport of spliced NS2 mRNA and its precursor NS1 mRNA. Genes Dev. 1992;6:255–67.PubMedCrossRef
84.
Alonso-Caplen FV, Krug RM. Regulation of the extent of splicing of influenza virus NS1 mRNA: role of the rates of splicing and of the nucleocytoplasmic transport of NS1 mRNA. Mol Cell Biol. 1991;11:1092–8.PubMedPubMedCentral
85.
Hu B, Li X, Huo Y, Yu Y, Zhang Q, Chen G, Zhang Y, Fraser NW, Wu D, Zhou J. Cellular responses to HSV-1 infection are linked to specific types of alterations in the host transcriptome. Sci Rep. 2016;6:28075.PubMedPubMedCentralCrossRef
86.
De Maio FA, Risso G, Iglesias NG, Shah P, Pozzi B, Gebhard LG, Mammi P, Mancini E, Yanovsky MJ, Andino R, et al. The dengue virus NS5 protein intrudes in the cellular spliceosome and modulates splicing. PLoS Pathog. 2016;12:e1005841.PubMedPubMedCentralCrossRef
87.
Li D, Su M, Sun PP, Guo WP, Wang CY, Wang JL, Wang H, Zhang Q, Du LY, Xie GC. Global profiling of the alternative splicing landscape reveals transcriptomic diversity during the early phase of enterovirus 71 infection. Virology. 2020;548:213–25.PubMedCrossRef
88.
Hu B, Huo Y, Yang L, Chen G, Luo M, Yang J, Zhou J. ZIKV infection effects changes in gene splicing, isoform composition and lncRNA expression in human neural progenitor cells. Virol J. 2017;14:217.PubMedPubMedCentralCrossRef
89.
90.
91.
Batra R, Stark TJ, Clark AE, Belzile JP, Wheeler EC, Yee BA, Huang H, Gelboin-Burkhart C, Huelga SC, Aigner S, et al. RNA-binding protein CPEB1 remodels host and viral RNA landscapes. Nat Struct Mol Biol. 2016;23:1101–10.PubMedPubMedCentralCrossRef
92.
Boudreault S, Durand M, Martineau CA, Perreault JP, Lemay G, Bisaillon M. Reovirus mu2 protein modulates host cell alternative splicing by reducing protein levels of U5 snRNP core components. Nucleic Acids Res. 2022;50:5263–81.PubMedPubMedCentralCrossRef
93.
94.
Pettit Kneller EL, Connor JH, Lyles DS. hnRNPs Relocalize to the cytoplasm following infection with vesicular stomatitis virus. J Virol. 2009;83:770–80.PubMedCrossRef
95.
Redondo N, Madan V, Alvarez E, Carrasco L. Impact of vesicular stomatitis virus M proteins on different cellular functions. PLoS ONE. 2015;10:e0131137.PubMedPubMedCentralCrossRef
96.
Song J, Quan R, Wang D, Liu J. Seneca valley virus 3C (pro) cleaves heterogeneous nuclear ribonucleoprotein K to facilitate viral replication. Front Microbiol. 2022;13:945443.PubMedPubMedCentralCrossRef
97.
Fitzgerald KD, Chase AJ, Cathcart AL, Tran GP, Semler BL. Viral proteinase requirements for the nucleocytoplasmic relocalization of cellular splicing factor SRp20 during picornavirus infections. J Virol. 2013;87:2390–400.PubMedPubMedCentralCrossRef
98.
Liu YC, Kuo RL, Lin JY, Huang PN, Huang Y, Liu H, Arnold JJ, Chen SJ, Wang RY, Cameron CE, Shih SR. Cytoplasmic viral RNA-dependent RNA polymerase disrupts the intracellular splicing machinery by entering the nucleus and interfering with Prp8. PLoS Pathog. 2014;10:e1004199.PubMedPubMedCentralCrossRef
99.
Banerjee AK, Blanco MR, Bruce EA, Honson DD, Chen LM, Chow A, Bhat P, Ollikainen N, Quinodoz SA, Loney C, et al. SARS-CoV-2 disrupts splicing, translation, and protein Trafficking to suppress host defenses. Cell. 2020;183(1325–1339):e1321.
100.
Slonchak A, Khromykh AA. Subgenomic flaviviral RNAs: what do we know after the first decade of research. Antiviral Res. 2018;159:13–25.PubMedCrossRef
101.
Roby JA, Pijlman GP, Wilusz J, Khromykh AA. Noncoding subgenomic flavivirus RNA: multiple functions in West Nile virus pathogenesis and modulation of host responses. Viruses. 2014;6:404–27.PubMedPubMedCentralCrossRef
102.
Bonenfant G, Meng R, Shotwell C, Badu P, Payne AF, Ciota AT, Sammons MA, Berglund JA, Pager CT. Asian zika virus isolate significantly changes the transcriptional profile and alternative RNA splicing events in a neuroblastoma cell line. Viruses-Basel. 2020. https://​doi.​org/​10.​3390/​v12050510.CrossRef
103.
Michalski D, Ontiveros JG, Russo J, Charley PA, Anderson JR, Heck AM, Geiss BJ, Wilusz J. Zika virus noncoding sfRNAs sequester multiple host-derived RNA-binding proteins and modulate mRNA decay and splicing during infection. J Biol Chem. 2019;294:16282–96.PubMedPubMedCentralCrossRef
104.
Liang J, Hong Z, Sun B, Guo Z, Wang C, Zhu J. The alternatively spliced isoforms of key molecules in the cGAS-STING signaling pathway. Front Immunol. 2021;12:771744.PubMedPubMedCentralCrossRef
105.
106.
Shang G, Zhang C, Chen ZJ, Bai XC, Zhang X. Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP. Nature. 2019;567:389–93.PubMedPubMedCentralCrossRef
107.
Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013;14:19–26.PubMedCrossRef
108.
Wang PH, Fung SY, Gao WW, Deng JJ, Cheng Y, Chaudhary V, Yuen KS, Ho TH, Chan CP, Zhang Y, et al. A novel transcript isoform of STING that sequesters cGAMP and dominantly inhibits innate nucleic acid sensing. Nucleic Acids Res. 2018;46:4054–71.PubMedPubMedCentralCrossRef
109.
Chen H, Pei R, Zhu W, Zeng R, Wang Y, Wang Y, Lu M, Chen X. An alternative splicing isoform of MITA antagonizes MITA-mediated induction of type I IFNs. J Immunol. 2014;192:1162–70.PubMedCrossRef
110.
Li C, Feng L, Luo WW, Lei CQ, Li M, Shu HB. The RNA-binding protein LUC7L2 mediates MITA/STING intron retention to negatively regulate innate antiviral response. Cell Discov. 2021;7:46.PubMedPubMedCentralCrossRef
111.
Deng W, Shi M, Han M, Zhong J, Li Z, Li W, Hu Y, Yan L, Wang J, He Y, et al. Negative regulation of virus-triggered IFN-beta signaling pathway by alternative splicing of TBK1. J Biol Chem. 2008;283:35590–7.PubMedCrossRef
112.
Hu YW, Zhang J, Wu XM, Cao L, Nie P, Chang MX. TANK-Binding Kinase 1 (TBK1) Isoforms negatively regulate type I interferon induction by inhibiting TBK1-IRF3 interaction and IRF3 phosphorylation. Front Immunol. 2018;9:84.PubMedPubMedCentralCrossRef
113.
Zhang J, Wu XM, Hu YW, Chang MX. A novel transcript isoform of TBK1 negatively regulates type I IFN production by promoting proteasomal degradation of TBK1 and lysosomal degradation of IRF3. Front Immunol. 2020;11:580864.PubMedPubMedCentralCrossRef
114.
115.
Walter MJ, Look DC, Tidwell RM, Roswit WT, Holtzman MJ. Targeted inhibition of interferon-gamma-dependent intercellular adhesion molecule-1 (ICAM-1) expression using dominant-negative Stat1. J Biol Chem. 1997;272:28582–9.PubMedCrossRef
116.
Han Z, Marendy E, Wang YD, Yuan J, Sample JT, Swaminathan S. Multiple roles of Epstein-Barr virus SM protein in lytic replication. J Virol. 2007;81:4058–69.PubMedPubMedCentralCrossRef
117.
118.
Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic. 2002;3:710–7.PubMedCrossRef
119.
Ku C-C, Che X-B, Reichelt M, Rajamani J, Schaap-Nutt A, Huang K-J, Sommer MH, Chen Y-S, Chen Y-Y, Arvin AM. Herpes simplex virus-1 induces expression of a novel MxA isoform that enhances viral replication. Immunol Cell Biol. 2011;89:173–82.PubMedCrossRef
120.
Chen Y, Graf L, Chen T, Liao Q, Bai T, Petric PP, Zhu W, Yang L, Dong J, Lu J, et al. Rare variant MX1 alleles increase human susceptibility to zoonotic H7N9 influenza virus. Science. 2021;373:918–22.PubMedCrossRef
Metadata
Title
Virus usurps alternative splicing to clear the decks for infection
Authors
Ruixue Li
Shenyan Gao
Huayuan Chen
Xiaozhan Zhang
Xia Yang
Jun Zhao
Zeng Wang
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Influenza Virus
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02098-9

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue

Research

SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort

Case Report

Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman

Research

Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis

Research

Development of an assay system for the analysis of host RISC activity in the presence of a potyvirus RNA silencing suppressor, HC-Pro

Research

Aloe-emodin inhibits African swine fever virus replication by promoting apoptosis via regulating NF-κB signaling pathway

Research

Global molecular evolution and phylogeographic analysis of barley yellow dwarf virus based on the cp and mp genes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits